Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported equity compensation awards in the form of stock options and restricted stock units. On March 5, 2026, he was granted stock options for 143,985 shares at an exercise price of $0.00 per share, and a separate grant of 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to his continued service. Twenty‑five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also subject to continued service. Additional common shares are held indirectly by various family trusts for which he serves as trustee, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
FRATES JAMES M
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 143,985 | $0.00 | -- |
| Grant/Award | Common Stock | 95,990 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 143,985 shares (Direct);
Common Stock — 261,628 shares (Direct);
Common Stock — 100,000 shares (Indirect, By Trust)
Footnotes (1)
- The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
FAQ
What insider transactions did AMLX CFO James M. Frates report on this Form 4?
James M. Frates reported receiving stock options for 143,985 shares and a restricted stock unit award for 95,990 shares of Amylyx common stock. Both equity awards were granted on March 5, 2026 at an exercise or purchase price of $0.00 per share.
How do the new Amylyx (AMLX) RSU awards to the CFO vest over time?
The restricted stock unit award for 95,990 shares vests in four equal annual installments. The first installment vests on March 1, 2027, with the remaining installments vesting on each of the next three anniversaries, subject to the CFO’s continued service to Amylyx.
What is the vesting schedule for the new Amylyx (AMLX) stock options granted to the CFO?
Of the 143,985 stock options granted, 25% vest and become exercisable on March 1, 2027. The remaining 75% vest in equal monthly installments over the following 36 months, contingent on the CFO’s continuous service with Amylyx Pharmaceuticals.